NextCure, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
NXTC Nasdaq 2836 www.nextcure.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NextCure, Inc.

NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference - Nov 20th, 2025 6:00 am
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts - Nov 17th, 2025 6:00 am
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules - Nov 12th, 2025 6:00 am
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect? - Nov 11th, 2025 7:55 am
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results - Nov 5th, 2025 2:05 pm
Companies Like NextCure (NASDAQ:NXTC) Could Be Quite Risky - Oct 18th, 2025 6:10 am
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States - Oct 16th, 2025 6:05 am
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 4th, 2025 5:00 am
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results - Aug 7th, 2025 2:05 pm
Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta - Jul 24th, 2025 2:05 pm
NextCure and Simcere partner to develop SIM0505 for solid tumours - Jun 17th, 2025 3:34 am
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 - Jun 16th, 2025 5:05 am
NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 - May 29th, 2025 9:03 pm
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 - May 29th, 2025 2:05 pm
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results - May 1st, 2025 2:05 pm
NextCure to Present at 24th Annual Needham Virtual Healthcare Conference - Apr 4th, 2025 5:00 am
NextCure Provides Business Update and Reports Full Year 2024 Financial Results - Mar 6th, 2025 2:05 pm
Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Feb 10th, 2025 5:32 am